NCT06744426View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 4, 2025

Primary Completion Date

March 12, 2025

Study Completion Date

March 12, 2025

Conditions
Essential Hypertension
Interventions
DRUG

BR1015

One tablet administered alone

DRUG

BR1015-2

One tablet administered alone

DRUG

BR1015-3

One tablet administered alone

Trial Locations (1)

08779

Clinical Research Center, H PLUS Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT06744426 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions | Biotech Hunter | Biotech Hunter